Patients Who Buy Mounjaro Privately Face Little Prospect of NHS Provision, Raising Questions Over Access

A growing number of British patients who have paid privately for Mounjaro (tirzepatide) are unlikely to receive NHS-funded prescriptions for the drug if they later seek it, clinicians and patients say, because NHS funding is allocated according to clinical eligibility and local commissioning rules rather than private purchase history.

Julia Dore, 51, said privately purchased Mounjaro has transformed her health — she lost five-and-a-half stone in six months, and her blood pressure, blood sugar and cholesterol levels fell sharply — but she now faces uncertainty about whether the treatment would be provided by the NHS if she sought it. Dore, who has a history of heart disease and struggled with her weight for decades, said the injections allowed her to resume everyday activities such as climbing stairs and walking her dog without breathlessness.

NHS services typically allocate medicines and treatments on the basis of nationally or locally agreed clinical criteria and budgetary arrangements. That means eligibility for NHS funding depends on whether a patient meets the clinical thresholds set out by national guidance or local clinical commissioning policies, rather than on whether they have previously paid for the same medicine privately.

Clinicians and NHS sources said demand for GLP-1 and related drugs, including tirzepatide, has surged as evidence accumulates of their effectiveness in weight loss and associated health improvements. The surge in demand has coincided with limited NHS commissioning for these agents for obesity in many areas, leading some patients to seek private prescriptions. Prices on the private market have risen as demand increased, and supply constraints have been reported in some clinics.

Patients who are considering private treatment or who have already started privately funded injections are being advised to consult their general practitioner to determine whether they meet NHS eligibility criteria. Clinical eligibility typically takes into account measures such as body mass index, the presence of obesity-related conditions and previous treatment attempts, as well as guidance from bodies that advise the NHS on the use of medicines.

Public health specialists say the rapid uptake of these medications has raised broader questions about equity of access. Some clinicians warn that private purchase can create disparities between patients who can afford treatment and those who rely on NHS care, particularly while commissioning decisions and guidance on the use of newer agents for weight management are still evolving.

Prescription of medications on the NHS also follows safety and licensing considerations. Mounjaro is licensed for the treatment of type 2 diabetes; its use for weight loss in people without diabetes is an area of clinical interest and ongoing study. NHS funding decisions take into account the licensed indications, clinical evidence, and the recommendations of advisory bodies when determining whether treatments should be routinely funded.

For patients already receiving privately funded injections, clinicians emphasize the importance of continuity of care. Sudden discontinuation of weight-loss medication can have health implications, and clinicians advise patients to seek medical guidance before stopping or changing their medication regimen. GPs can advise on monitoring, alternative therapies available on the NHS, and whether a patient’s clinical circumstances make them eligible for NHS-funded treatment under local policies.

NHS authorities and local clinical commissioners have responsibility for setting funding priorities within constrained budgets, and those priorities differ across regions. That can mean that two patients with similar clinical profiles may face different funding outcomes depending on where they live.

As demand for GLP-1 receptor agonists and related drugs continues to grow, NHS officials, clinicians and patient groups are watching commissioning decisions and emerging clinical evidence closely. The situation highlights the tension between rapid uptake of new therapies in private practice and the processes by which publicly funded health systems evaluate and fund treatments for the wider population.

Patients seeking clarity on their own eligibility are advised to contact their GP or local NHS commissioning body for information specific to their circumstances and to avoid altering medication without medical advice.